PARKINSON DISEASE ADAGIO trial hints that rasagiline slows disease progression

the results of the ADAGIO trial, combined with those of the TEMPO trial and a large body of additional clinical and preclinical data, indicate that the possibility of treatment with rasagiline should be discussed with all patients with early Parkinson disease.